BR0108893B1 - composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos. - Google Patents

composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.

Info

Publication number: BR0108893B1
Authority: BR; Brazil
Prior art keywords: azetidine; preparation; compounds; pharmaceutical composition; composition containing
Prior art date: 2000-03-03

Application number

BRPI0108893-9A

Other languages

English (en)

Other versions

BR0108893A (pt

Inventor

Daniel Achard

Herve Bouchard

Jean Bouquerel

Bruno Filoche

Serge Grisoni

Augustin Hittinger

Michael Myers

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-03

Filing date

2001-03-01

Publication date

2013-06-04

2001-03-01 Application filed filed Critical

2002-11-05 Publication of BR0108893A publication Critical patent/BR0108893A/pt

2013-06-04 Publication of BR0108893B1 publication Critical patent/BR0108893B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Nutrition Science (AREA)
Otolaryngology (AREA)

BRPI0108893-9A 2000-03-03 2001-03-01 composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos. BR0108893B1 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0002776A FR2805817B1 (fr)	2000-03-03	2000-03-03	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
PCT/FR2001/000602 WO2001064634A1 (fr)	2000-03-03	2001-03-01	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation

Publications (2)

Publication Number	Publication Date
BR0108893A BR0108893A (pt)	2002-11-05
BR0108893B1 true BR0108893B1 (pt)	2013-06-04

Family

ID=8847706

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0108893-9A BR0108893B1 (pt)	2000-03-03	2001-03-01	composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.

Country Status (36)

Country	Link
EP (1)	EP1263722B1 (pt)
JP (1)	JP4883867B2 (pt)
KR (1)	KR100819572B1 (pt)
CN (1)	CN100386314C (pt)
AT (1)	ATE478841T1 (pt)
AU (1)	AU780880B2 (pt)
BG (1)	BG66001B1 (pt)
BR (1)	BR0108893B1 (pt)
CA (1)	CA2400141C (pt)
CY (1)	CY1111071T1 (pt)
CZ (1)	CZ301254B6 (pt)
DE (1)	DE60142891D1 (pt)
DK (1)	DK1263722T3 (pt)
DZ (1)	DZ3312A1 (pt)
EA (1)	EA007109B1 (pt)
EE (1)	EE05103B1 (pt)
ES (1)	ES2351276T3 (pt)
FR (1)	FR2805817B1 (pt)
HR (1)	HRP20020712B1 (pt)
HU (1)	HUP0400636A3 (pt)
IL (2)	IL151321A0 (pt)
MA (1)	MA26880A1 (pt)
ME (1)	MEP9509A (pt)
MX (1)	MXPA02008349A (pt)
NO (1)	NO324524B1 (pt)
NZ (1)	NZ521077A (pt)
OA (1)	OA12222A (pt)
PL (1)	PL208021B1 (pt)
PT (1)	PT1263722E (pt)
SI (1)	SI1263722T1 (pt)
SK (1)	SK287445B6 (pt)
TW (1)	TWI304399B (pt)
UA (1)	UA73554C2 (pt)
WO (1)	WO2001064634A1 (pt)
YU (1)	YU66002A (pt)
ZA (1)	ZA200206912B (pt)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002022579A2 (en)	2000-09-11	2002-03-21	Sepracor, Inc.	Antipsychotic sulfonamide-heterocycles, and methods of use thereof
FR2814678B1 (fr) *	2000-10-04	2002-12-20	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en)	2000-10-04	2002-07-11	Odile Piot-Grosjean	Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2003007887A2 (en)	2001-07-20	2003-01-30	Merck & Co., Inc.	Substituted imidazoles as cannabinoid receptor modulators
FR2833842B1 (fr) *	2001-12-21	2004-02-13	Aventis Pharma Sa	Compositions pharmaceutiques a base de derives d'azetidine
EP1487436A4 (en)	2002-03-08	2009-06-03	Signal Pharm Inc	POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
JP3813152B2 (ja)	2002-03-12	2006-08-23	メルクエンドカムパニーインコーポレーテッド	置換アミド類
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
AU2003250117B2 (en)	2002-07-29	2007-05-10	F. Hoffmann-La Roche Ag	Novel benzodioxoles
AU2003293968A1 (en)	2003-01-02	2004-07-29	F. Hoffmann-La Roche Ag	Novel cb 1 receptor inverse agonists
WO2004060870A1 (en)	2003-01-02	2004-07-22	F. Hoffmann-La Roche Ag	Novel cb 1 receptour inverse agonists
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7514562B2 (en) *	2003-03-07	2009-04-07	Glaxo Group Limited	Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
CA2524245A1 (en) *	2003-05-01	2004-11-11	Vernalis Research Limited	The use of azetidinecarboxamide derivatives in therapy
US20040224962A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
KR20060019587A (ko)	2003-06-11	2006-03-03	머크 앤드 캄파니 인코포레이티드	치환된 3-알킬 및 3-알케닐 아제티딘 유도체
KR100809201B1 (ko)	2003-06-20	2008-02-29	에프. 호프만-라 로슈 아게	카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
ES2298840T3 (es)	2003-12-08	2008-05-16	F. Hoffmann-La Roche Ag	Derivados de tiazol.
CA2553970A1 (en)	2004-01-28	2005-08-18	F. Hoffmann-La Roche Ag	Spiro-benzodioxoles and their use as cb1 antagonists
EP1574211A1 (en)	2004-03-09	2005-09-14	Inserm	Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP1749002B1 (en)	2004-05-10	2009-05-27	F.Hoffmann-La Roche Ag	Pyrrole or imidazole amides for treating obesity
FR2876688B1 (fr) *	2004-10-14	2007-03-16	Aventis Pharma Sa	Nouveau produit, procede et intermediaires de preparation de derives d'azetidine
FR2876689B1 (fr) *	2004-10-14	2008-02-22	Aventis Pharma Sa	Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
KR100912146B1 (ko)	2004-10-27	2009-08-14	에프. 호프만-라 로슈 아게	인돌 또는 벤즈이미다졸 유도체
JP4675969B2 (ja)	2004-11-09	2011-04-27	エフ．ホフマン−ラロシュアーゲー	ジベンゾスベロン誘導体
KR100970050B1 (ko)	2005-04-06	2010-07-16	에프. 호프만-라 로슈 아게	Ｃｂ1 역 작용제로서 피리딘-3-카복사마이드 유도체
BRPI0610580B8 (pt)	2005-05-30	2021-05-25	Banyu Pharma Co Ltd	composto derivado de piperidina
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2007018248A1 (ja)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	ピリドン化合物
CA2619770A1 (en)	2005-08-24	2007-03-01	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
US20090264426A1 (en)	2005-09-07	2009-10-22	Shunji Sakuraba	Bicyclic aromatic substituted pyridone derivative
CA2624030A1 (en)	2005-09-29	2007-04-12	Tianying Jian	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US8163770B2 (en)	2005-10-27	2012-04-24	Msd. K. K.	Benzoxathiin derivative
AU2006312557B2 (en)	2005-11-10	2011-12-08	Msd K.K.	Aza-substituted spiro derivative
US7906652B2 (en)	2005-11-28	2011-03-15	Merck Sharp & Dohme Corp.	Heterocycle-substituted 3-alkyl azetidine derivatives
AR058199A1 (es) *	2005-11-28	2008-01-23	Merck & Co Inc	Derivados de 3- alquilazetidina sustituidos con heterociclos
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US7781593B2 (en)	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
CA2770486C (en)	2006-09-22	2014-07-15	Merck Sharp & Dohme Corp.	Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008047544A1 (fr)	2006-09-28	2008-04-24	Banyu Pharmaceutical Co., Ltd.	Dérivé diarylcétimine
US8106086B2 (en)	2007-04-02	2012-01-31	Msd K.K.	Indoledione derivative
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru)	2007-06-04	2014-11-28	Синерджи Фармасьютикалз Инк.	Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
FR2925050B1 (fr) *	2007-12-14	2010-01-08	Sanofi Aventis	Nouveau procede de preparation de derives d'azetidine
JP5460614B2 (ja) *	2007-12-18	2014-04-02	サノフイ	アゼチジン誘導体、それらの調製、およびそれらの治療における適用
FR2930941B1 (fr) *	2008-05-06	2010-06-18	Sanofi Aventis	Derives d'azetidines, leur preparation et leur application en therapeutique
FR2928149B1 (fr)	2008-02-29	2011-01-14	Sanofi Aventis	Composes derives d'azetidines, leur preparation et leur application en therapeutique
CN101981025A (zh)	2008-03-28	2011-02-23	万有制药株式会社	具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
CA2930674A1 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (ja)	2008-06-19	2011-12-01	Ｍｓｄ株式会社	スピロジアミン−ジアリールケトオキシム誘導体
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2731358A1 (en)	2008-07-30	2010-02-04	Banyu Pharmaceutical Co., Ltd.	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
FR2934996B1 (fr) *	2008-08-14	2010-08-27	Sanofi Aventis	Composes polysubstitues d'azetidines, leur preparation et leur application en therapeutique
FR2934995B1 (fr) *	2008-08-14	2010-08-27	Sanofi Aventis	Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
JP5575137B2 (ja)	2008-10-22	2014-08-20	メルク・シャープ・アンド・ドーム・コーポレーション	抗糖尿病剤として有用な新規な環状ベンゾイミダゾール誘導体
JP5635991B2 (ja)	2008-10-30	2014-12-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	イソニコチンアミドオレキシン受容体アンタゴニスト
US8329914B2 (en)	2008-10-31	2012-12-11	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010056717A1 (en)	2008-11-17	2010-05-20	Merck Sharp & Dohme Corp.	Substituted bicyclic amines for the treatment of diabetes
FR2946650B1 (fr) *	2009-06-16	2011-08-19	Sanofi Aventis	Esters derives d'azetidines, leur preparation et leur application en therapeutique.
WO2011011506A1 (en)	2009-07-23	2011-01-27	Schering Corporation	Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en)	2009-07-23	2011-01-27	Schering Corporation	Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
BR112012003973A2 (pt)	2009-08-26	2015-09-08	Sanofi Sa	hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2563764B1 (en)	2010-04-26	2015-02-25	Merck Sharp & Dohme Corp.	Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en)	2010-05-11	2016-10-26	Merck Sharp & Dohme Corp.	Novel prolylcarboxypeptidase inhibitors
EP2579873A4 (en)	2010-06-11	2013-11-27	Merck Sharp & Dohme	NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2012116145A1 (en)	2011-02-25	2012-08-30	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2880028B1 (en)	2012-08-02	2020-09-30	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
BR112015019836A2 (pt)	2013-02-22	2017-07-18	Merck Sharp & Dohme	composto, composição farmacêutica, e, uso de um composto
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US10011637B2 (en)	2013-06-05	2018-07-03	Synergy Pharmaceuticals, Inc.	Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2016030534A1 (en)	2014-08-29	2016-03-03	Tes Pharma S.R.L.	INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
CA3038185A1 (en)	2016-10-14	2018-04-19	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
KR20210111248A (ko)	2018-11-20	2021-09-10	테스 파마 에스.알.엘.	α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
US20230018413A1 (en)	2019-08-08	2023-01-19	Merck Sharp & Dohme Corp.	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4200295A1 (en)	2020-08-18	2023-06-28	Merck Sharp & Dohme LLC	Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4242261A (en) *	1979-07-19	1980-12-30	A. H. Robins Company, Inc.	Production of methylene-cycloamines
FR2649100B1 (fr) *	1989-06-29	1994-03-04	Laboratorios Dr Esteve Sa	Nouvelles azetidines, leur preparation et leur application comme intermediaires pour la preparation de composes avec activite antimicrobienne
US5556861A (en) *	1991-10-01	1996-09-17	Laboratoire Roger Bellon	1,8 benzonaphthyridine derivatives and antimicrobial compositions
CA2166975C (en) *	1993-07-16	2005-04-05	Mark G. Bock	Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5545636A (en) *	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
WO1997001556A1 (en) *	1995-06-29	1997-01-16	Novo Nordisk A/S	Novel substituted azacyclic or azabicyclic compounds
GB9714129D0 (en) *	1997-07-04	1997-09-10	Pfizer Ltd	Azetidines

2000
- 2000-03-03 FR FR0002776A patent/FR2805817B1/fr not_active Expired - Fee Related
2001
- 2001-01-03 UA UA2002097701A patent/UA73554C2/uk unknown
- 2001-02-23 TW TW090104187A patent/TWI304399B/zh not_active IP Right Cessation
- 2001-03-01 ME MEP-95/09A patent/MEP9509A/xx unknown
- 2001-03-01 CZ CZ20022923A patent/CZ301254B6/cs not_active IP Right Cessation
- 2001-03-01 DZ DZ013312A patent/DZ3312A1/fr active
- 2001-03-01 DK DK01909939.9T patent/DK1263722T3/da active
- 2001-03-01 EA EA200200938A patent/EA007109B1/ru not_active IP Right Cessation
- 2001-03-01 KR KR1020027011517A patent/KR100819572B1/ko not_active IP Right Cessation
- 2001-03-01 EE EEP200200485A patent/EE05103B1/xx not_active IP Right Cessation
- 2001-03-01 CN CNB018066437A patent/CN100386314C/zh not_active Expired - Fee Related
- 2001-03-01 PL PL365046A patent/PL208021B1/pl unknown
- 2001-03-01 CA CA2400141A patent/CA2400141C/fr not_active Expired - Fee Related
- 2001-03-01 IL IL15132101A patent/IL151321A0/xx unknown
- 2001-03-01 HU HU0400636A patent/HUP0400636A3/hu unknown
- 2001-03-01 PT PT01909939T patent/PT1263722E/pt unknown
- 2001-03-01 AT AT01909939T patent/ATE478841T1/de active
- 2001-03-01 YU YU66002A patent/YU66002A/sh unknown
- 2001-03-01 DE DE60142891T patent/DE60142891D1/de not_active Expired - Lifetime
- 2001-03-01 OA OA1200200270A patent/OA12222A/fr unknown
- 2001-03-01 JP JP2001563477A patent/JP4883867B2/ja not_active Expired - Fee Related
- 2001-03-01 ES ES01909939T patent/ES2351276T3/es not_active Expired - Lifetime
- 2001-03-01 BR BRPI0108893-9A patent/BR0108893B1/pt not_active IP Right Cessation
- 2001-03-01 SK SK1243-2002A patent/SK287445B6/sk not_active IP Right Cessation
- 2001-03-01 SI SI200130981T patent/SI1263722T1/sl unknown
- 2001-03-01 AU AU37527/01A patent/AU780880B2/en not_active Ceased
- 2001-03-01 MX MXPA02008349A patent/MXPA02008349A/es active IP Right Grant
- 2001-03-01 NZ NZ521077A patent/NZ521077A/en unknown
- 2001-03-01 EP EP01909939A patent/EP1263722B1/fr not_active Expired - Lifetime
- 2001-03-01 WO PCT/FR2001/000602 patent/WO2001064634A1/fr active IP Right Grant
2002
- 2002-08-18 IL IL151321A patent/IL151321A/en not_active IP Right Cessation
- 2002-08-28 MA MA26794A patent/MA26880A1/fr unknown
- 2002-08-28 ZA ZA200206912A patent/ZA200206912B/en unknown
- 2002-08-30 HR HRP20020712AA patent/HRP20020712B1/hr not_active IP Right Cessation
- 2002-09-02 NO NO20024177A patent/NO324524B1/no not_active IP Right Cessation
- 2002-09-03 BG BG107058A patent/BG66001B1/bg unknown
2010
- 2010-11-18 CY CY20101101042T patent/CY1111071T1/el unknown

Also Published As

Publication number	Publication date
HUP0400636A2 (hu)	2004-06-28
EE05103B1 (et)	2008-12-15
NO324524B1 (no)	2007-11-12
TWI304399B (en)	2008-12-21
IL151321A (en)	2008-11-03
OA12222A (fr)	2006-05-10
WO2001064634A1 (fr)	2001-09-07
ES2351276T3 (es)	2011-02-02
HRP20020712B1 (hr)	2012-11-30
MA26880A1 (fr)	2004-12-20
DZ3312A1 (fr)	2001-09-07
SI1263722T1 (sl)	2010-12-31
NO20024177L (no)	2002-10-29
JP2003525270A (ja)	2003-08-26
BG107058A (bg)	2003-07-31
SK12432002A3 (sk)	2003-06-03
NZ521077A (en)	2004-09-24
SK287445B6 (sk)	2010-10-07
CN1418192A (zh)	2003-05-14
EA007109B1 (ru)	2006-06-30
CY1111071T1 (el)	2015-06-11
CA2400141C (fr)	2012-02-21
MXPA02008349A (es)	2002-12-13
EA200200938A1 (ru)	2003-02-27
FR2805817B1 (fr)	2002-04-26
EP1263722A1 (fr)	2002-12-11
HUP0400636A3 (en)	2004-09-28
CZ301254B6 (cs)	2009-12-23
PL208021B1 (pl)	2011-03-31
YU66002A (sh)	2005-09-19
MEP9509A (en)	2011-12-20
NO20024177D0 (no)	2002-09-02
AU780880B2 (en)	2005-04-21
PT1263722E (pt)	2010-11-23
EP1263722B1 (fr)	2010-08-25
BG66001B1 (bg)	2010-09-30
CA2400141A1 (fr)	2001-09-07
DK1263722T3 (da)	2011-01-03
HRP20020712A2 (en)	2005-10-31
JP4883867B2 (ja)	2012-02-22
EE200200485A (et)	2004-02-16
KR100819572B1 (ko)	2008-04-04
CN100386314C (zh)	2008-05-07
DE60142891D1 (de)	2010-10-07
BR0108893A (pt)	2002-11-05
KR20020075469A (ko)	2002-10-04
PL365046A1 (en)	2004-12-27
FR2805817A1 (fr)	2001-09-07
AU3752701A (en)	2001-09-12
ZA200206912B (en)	2003-11-03
ATE478841T1 (de)	2010-09-15
IL151321A0 (en)	2003-04-10
UA73554C2 (en)	2005-08-15

Publication	Publication Date	Title
BR0108893B1 (pt)	2013-06-04	composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
AU2002211216A1 (en)	2002-04-02	Substituted aminopropoxyaryl derivatives useful as agonists for lxr
ATE297203T1 (de)	2005-06-15	Antithrombotische mitteln
ATE273305T1 (de)	2004-08-15	Thrombin-inhibitoren
BR0116299A (pt)	2004-03-02	Composto, composição farmacêutica, método para o tratamento ou profilaxia de uma infecção picornaviral em um mamìfero, e, uso de um composto
DE602004008098D1 (de)	2007-09-20	Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MXPA02012033A (es)	2003-04-25	Derivados de 2-aminocarbonil-9h-purina.
WO2003082205A3 (en)	2009-04-16	Compounds and methods
ES2243579T3 (es)	2005-12-01	Derivados de pirazolopirideno.
MXPA05011176A (es)	2005-12-14	Derivados de carboxamida como agentes antidiabeticos.
NO20054787D0 (no)	2005-10-18	Indenderivater som farmasotiske midler
AU2003223340A1 (en)	2003-10-13	Certain pharmaceutically useful substituted aminoalkyl heterocycles
DE60114640D1 (en)	2005-12-08	Antithrombosemittel
EA200201024A1 (ru)	2003-02-27	Фармацевтические композиции, содержащие олигосахариды, и их получение
BR0009795A (pt)	2002-01-08	Processo para a ppeparação de um composto da fórmula (i), e, composto
EA200100953A1 (ru)	2002-02-28	L-арабино-дисахариды антрациклинов, способы их получения и фармацевтические композиции, содержащие их
AP2001002179A0 (en)	2002-11-30	2-Aminocarbonyl-9h-purine derivatives.
BR9915898A (pt)	2001-08-21	Compostos, composição farmacêutica, e, utilização de um composto
ECSP992966A (es)	1999-07-08	Compuestos de amindazol

Legal Events

Date	Code	Title	Description
2011-02-22	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2011-02-22	B15K	Others concerning applications: alteration of classification	Free format text: ALTERADA DA INT.CL: C07D 205/04, C07D 401/12, C07D 403/12, C07D 417/12, A61K 31/397, A61P 25/00 Ipc: A61K 31/397 (2011.01), A61K 31/425 (2011.01), A61K
2011-08-09	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2012-02-22	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2013-02-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2013-04-02	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2013-06-04	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2013, OBSERVADAS AS CONDICOES LEGAIS.
2016-05-10	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2016-08-30	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2366 DE 10-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.